Reta glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking approach to diabetes management. These innovative therapies work by mimicking the natural actions of GLP-1, a hormone produced by the gut in response to food. By activating GLP-1 receptors in the pancreas, these agents boost insulin production and suppress glucagon ou

The burgeoning landscape of novel treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a comparable therapeutic goal – improving glycemic control and promoting considerable weight decrease – they exhibit intriguing contrasts in the